Postsurgical thyroid remnant estimation by 99mTc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma
✍ Scribed by Luca Giovanella; Sergio Suriano; Riccardo Ricci; Luca Ceriani; Frederik Anton Verburg
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 93 KB
- Volume
- 33
- Category
- Article
- ISSN
- 1043-3074
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Background.
The purpose of this study was to evaluate the relationship between postsurgical neck ^99m^technetium (^99m^Tc)‐pertechnetate uptake and the rate of successful remnant ablation after radioiodine treatment in patients with differentiated thyroid carcinoma (DTC).
Methods.
Retrospectively enrolled were 232 patients with DTC who underwent total thyroidectomy and fixed activity ablation with 3.7 GBq ^131^I. The ^99m^Tc scans were performed on all patients before ^131^I administration. Thyroid ablation was assessed after 6 to 12 months by thyroid‐stimulating hormone (TSH)‐stimulated ^131^I‐WBS and thyroglobulin measurement. The rate of successful ablation, occurrence of radioiodine‐induced thyroiditis, and length of hospitalization were correlated with the ^99m^Tc‐pertechnetate scintigraphy results.
Results.
A ^99m^Tc uptake was significantly lower in ablated versus nonablated patients (p < .001). High ^99m^Tc‐pertechnetate uptake, especially greater than 1.4%, predicted a high‐risk of unsuccessful ablation. Higher ^99m^Tc‐pertechnetate uptake was also related to prolonged hospitalization and the occurrence of radioiodine‐induced thyroiditis.
Conclusion.
The ^99m^Tc‐pertechnetate scintigraphy is a simple and feasible tool to evaluate thyroid remnants and to predict radioiodine ablation results in patients with DTC. © 2010 Wiley Periodicals, Inc. Head Neck, 2011